Previous close | 122.10 |
Open | 122.10 |
Bid | 110.90 |
Ask | 113.40 |
Strike | 230.00 |
Expiry date | 2025-01-17 |
Day's range | 122.10 - 122.10 |
Contract range | N/A |
Volume | |
Open interest | 28 |
BioNTech stock lifted a fraction Monday after Covid vaccine sales dropped again in the first quarter, amid wide losses.
Monday, BioNTech SE (NASDAQ:BNTX) reported a first-quarter EPS loss of 1.31 euros ($1.41 loss), a shift from an income of 2.05 euros, missing the consensus loss of 97 cents. The COVID-19 vaccine maker reported sales of 187.6 million euros (roughly $202 million), down from 1.3 billion euros reported a year ago, missing the consensus of 427.5 million euros. The European biotech firm posted a quarterly net loss of 315 million euros, compared with a profit of 502 million a year earlier. “We expect t
The pharmaceutical company posts a first-quarter loss of €1.31 a share, a swing from year-earlier profit of €2.05.